Ascendis Pharma A/S
NASDAQ:ASNDBiotechnology
-$0.05 today
- Market cap
- $17.73B
- Beta
- 0.39
- P/E (TTM)
- 24.5
- EPS (TTM)
- $8.21
Volume 0.57M
Average 0.64M
ASND Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Ascendis Pharma A/SNASDAQ: ASND
Revenue · Q3 FY2026 · quarter ended Sep 2026
Revenue grows, but more slowly than its trailing trend
Q3 FY2026 revenue of €367.46M rose 72.0% year over year, behind the +86.9% change in trailing-twelve-month revenue. Sequentially, it rose 6.5% from the prior quarter. Over 3 fiscal years it compounded at +138.2% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 13 analysts of €1.35B (+95.7%) for the fiscal year ending Dec 2026, a step up from the +90.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- €367.46M+6.5% QoQ
- Last fiscal yearDec 2025
- €691.71M+90.2% YoY
- LTMSep 2026
- €1.21B+86.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +72.0% | +67.8% | -4.2 pp |
| 1 year | +90.2% | +95.7% | +5.5 pp |
| 3-year CAGR | +138.2% | +53.9% | -84.3 pp |
| 5-year CAGR | +37.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
EUR · from the income statement
- Latest · FY2025
- 691.71M EUR
- Year-over-year change
- +90.2%
- 4-year CAGR
- +207.1%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 691.71M | +90.2% |
| FY2024 | 2024-12-31 | 363.64M | +36.3% |
| FY2023 | 2023-12-31 | 266.72M | +421.2% |
| FY2022 | 2022-12-31 | 51.17M | +557.9% |
| FY2021 | 2021-12-31 | 7.78M | — |
Revenue vs competitors
How ASND compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +86.9% is the 4th highest of 10, against a peer median of +38.0%.
- Over three fiscal years its annual growth of +138.2% compares with a peer median of +24.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $1.03T USD | +33102.2% | +15.4% | |
| LTM Sep 2026 | $3.7B USD | +38.0% | +24.3% | |
| LTM Jun 2026 | $3.15B USD | +2.5% | +18.0% | |
| LTM Sep 2026 | €1.21B EUR | +86.9% | +138.2% | |
| LTM Jun 2026 | $1.14B USD | +185.8% | +35.2% | |
| LTM Jun 2026 | $830.81M USD | +16.0% | +23.7% | |
| LTM Mar 2026 | $669.43M USD | +13.3% | +22.8% | |
| LTM Mar 2026 | $314.85M USD | +41.5% | +38.3% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $96.27M USD | +336.7% | — |
| LTM Mar 2026 | $32.08M USD | -83.2% | +145.9% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $0 USD | — | — |
| Peer median (excluding ASND) | — | +38.0% | +24.0% | |
Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.78M | 51.17M | 266.72M | 363.64M | 691.71M |
| Cost of Revenue | 3.52M | 12.14M | 44.4M | 44.26M | 103.18M |
| Gross Profit | 4.26M | 39.04M | 222.32M | 319.38M | 588.53M |
| Gross Margin | 54.7% | 76.3% | 83.4% | 87.8% | 85.1% |
| Research & Development | 295.87M | 379.62M | 413.45M | 307M | 283.5M |
| Selling, General & Admin | 160.18M | 215.85M | 258.79M | 284.55M | 435.92M |
| Operating Expenses | 456.05M | 600.85M | 677.86M | 598.15M | 719.42M |
| Depreciation & Amortization | 15.39M | 17.96M | 18.91M | 17.71M | 17M |
| EBITDA | (364.64M) | (529.18M) | (411.17M) | (290.02M) | (109.8M) |
| EBITDA Margin | -4688.1% | -1034.1% | -154.2% | -79.8% | -15.9% |
| Operating Income | (451.79M) | (561.81M) | (455.54M) | (278.76M) | (130.89M) |
| Operating Margin | -5808.6% | -1097.9% | -170.8% | -76.7% | -18.9% |
| Interest Income | 692K | 7.43M | 16.86M | 14.36M | 14.7M |
| Interest Expense | 3.91M | 30.68M | 44.07M | 65.5M | 77.46M |
| Other Income / Expenses | 67.85M | (16M) | (18.6M) | (94.48M) | (73.37M) |
| Income Before Tax | (383.94M) | (577.82M) | (474.14M) | (373.24M) | (204.26M) |
| Pre-Tax Margin | -4936.3% | -1129.1% | -177.8% | -102.6% | -29.5% |
| Income Tax Expense | (367K) | 5.38M | 7.3M | 4.84M | 14.78M |
| Net Income | (383.58M) | (583.19M) | (481.45M) | (378.08M) | (219.03M) |
| Net Margin | -4931.6% | -1139.6% | -180.5% | -104.0% | -31.7% |
| EPS (Basic) | (7.00) | (10.40) | (8.55) | (6.53) | (3.62) |
| EPS (Diluted) | (7.00) | (10.40) | (8.55) | (6.53) | (3.62) |
| Weighted Avg Shares | 54.77M | 56.07M | 56.29M | 57.89M | 60.61M |
| Weighted Avg Shares (Diluted) | 54.77M | 56.07M | 56.29M | 57.89M | 60.61M |
Ascendis Pharma A/S
NASDAQ:ASND
Intrinsic Alpha fair value
Locked
Current Price
$270.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.